Boston Scientific (BSX) - news

• 6/17/13 5:05PM Boston Scientific begins patient enrollment in U.S. clinical trial for use of Cercise DBS system in treatment of Parkinson's disease (BSX) 9.64 +0.13 : Co announces the first implantation of its Vercise DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson's disease. The Vercise DBS System is a neurostimulation device that delivers electrical signals to specific areas within the brain through individual lead contacts. It is the only system that allows physicians to adjust the current flow in fine increments based on patient needs.